HBV DNA Quantitative Viral Load

Liver

Report in 12Hrs

At Home

No Fasting Required

Details

Measure the amount of Hepatitis B virus (HBV) DNA in a patient’s blood.

₹1,599₹8,250

81% OFF

HBV DNA Quantitative Viral Load - Comprehensive Medical Test Guide

Section 1: Why is it done?
- Test Purpose: Measures the amount of hepatitis B virus (HBV) DNA in the blood. This quantitative assessment determines viral replication levels and infectious burden in patients with chronic or acute hepatitis B infection.
- Primary Indications: Diagnosis of hepatitis B infection status and disease severity
- Monitoring response to antiviral therapy (tenofovir, lamivudine, entecavir, etc.)
- Assessing disease progression and risk of cirrhosis or hepatocellular carcinoma
- Determining infectivity and likelihood of transmission to others
- Detecting treatment-resistant viral mutants
- Timing of Testing: Performed at initial diagnosis, every 3-6 months during treatment, after treatment completion, and when evaluating treatment efficacy or suspected treatment failure
Section 2: Normal Range
- Reference Range: Negative/Undetectable (Normal): <10 IU/mL or <20 IU/mL depending on assay sensitivity and lower limit of quantitation
- Units of Measurement: International Units per milliliter (IU/mL) or copies per milliliter (copies/mL). 1 IU = approximately 0.3-0.4 copies
- Interpretation of Results:
- Negative/Undetectable: <10 IU/mL indicates no active viral replication; patient is not infected or has achieved viral suppression with treatment
- Detectable: ≥10 IU/mL indicates active HBV infection with viral replication
- Low-Level Viremia: 10-1,000 IU/mL (minimal viral replication)
- Moderate Viremia: 1,000-1,000,000 IU/mL (clinically significant replication)
- High Viremia: >1,000,000 IU/mL (extensive viral replication with high infectivity)
- Assay Sensitivity: Most modern assays have a lower limit of detection of 10-20 IU/mL (sensitive) to 200-400 IU/mL (less sensitive)
Section 3: Interpretation
- Result Value Interpretation:
- Undetectable (<10 IU/mL): Indicates successful viral suppression with treatment or absence of active infection; associated with reduced transmission risk and halted disease progression
- 10-100 IU/mL: Borderline low viremia; may represent successful treatment response or occult infection; requires clinical context
- 100-1,000 IU/mL: Low viremia but active replication; indicates disease is present but relatively controlled
- 1,000-10,000 IU/mL: Moderate viremia; indicates active disease that typically warrants treatment initiation if HBsAg and liver enzymes are elevated
- 10,000-100,000 IU/mL: High viremia; associated with active hepatitis, inflammation, and significant risk of disease progression
- >100,000-1,000,000 IU/mL: Very high viremia; indicates severe active replication with high infectivity and risk of transmission
- >1,000,000 IU/mL: Extremely high viremia; associated with acute hepatitis, rapid disease progression, and maximum transmission risk
- Clinical Significance: Viral load correlates with disease activity and prognosis. Generally, higher levels indicate greater liver inflammation, necrosis, and risk of developing cirrhosis or hepatocellular carcinoma (HCC)
- Factors Affecting Results:
- Natural fluctuations in viral replication (flares and remission phases)
- Antiviral medication adherence and efficacy
- HBV genotype (genotypes A and B typically have lower viral loads than C and D)
- Stage of chronic infection (immune tolerance, immune clearance, and low replicative phases)
- Presence of resistant mutants (precore, core promoter mutations; BCP mutations)
- Immunological status (lower in HIV co-infected patients with CD4+ <200 cells/mm³)
- Hepatitis D (Delta) co-infection (may suppress HBV replication)
- Treatment Response Patterns:
- Good Response: ≥2 log drop in viral load within 3-6 months of therapy initiation, progressing toward undetectability
- Poor Response: <1 log drop or rising viral load despite treatment; suggests poor adherence, resistant mutant, or inappropriate therapy
- Virological Breakthrough: Increasing viral load after initial response; indicates treatment failure or emergence of resistance mutations
Section 4: Associated Organs
- Primary Organ System: Hepatobiliary system; specifically the liver (hepatocytes are the primary site of HBV replication)
- Associated Conditions and Diseases:
- Acute Hepatitis B: Self-limited infection with acute inflammation; typically resolves within 6 months in immunocompetent adults
- Chronic Hepatitis B: Persistent infection (>6 months); HBsAg remains positive with viral replication
- Cirrhosis: Progressive liver fibrosis leading to end-stage liver disease; characterized by loss of hepatic function and portal hypertension
- Hepatocellular Carcinoma (HCC): Malignant transformation of hepatocytes; significantly increased risk with high viral loads and cirrhosis
- Acute Liver Failure: Fulminant hepatitis with rapid loss of hepatic synthetic function; can occur with acute HBV or superinfection with HDV
- Occult Hepatitis B: Presence of HBV DNA without detectable HBsAg; occurs in resolved or latent infection
- Complications of High Viral Load:
- Portal hypertension and variceal bleeding
- Hepatic encephalopathy
- Ascites and spontaneous bacterial peritonitis
- Hepatorenal syndrome
- Coagulopathy and hepatic thrombocytopenia
- Extrahepatic Manifestations:
- Immune complex-mediated glomerulonephritis and membranoproliferative disease
- Polyarteritis nodosa (systemic vasculitis)
- Cryoglobulinemia and arthritis
- Serum sickness-like reactions
Section 5: Follow-up Tests
- Serological Tests to Complement HBV DNA:
- HBsAg (Hepatitis B Surface Antigen): Indicates active infection; must be positive to diagnose HBV
- Anti-HBs (Hepatitis B Surface Antibody): Indicates immunity or resolved infection
- HBeAg (Hepatitis B e-Antigen): Indicates high infectivity and active viral replication
- Anti-HBe (Hepatitis B e-Antibody): Indicates lower infectivity and reduced replication (seroconversion)
- Anti-HBc (Hepatitis B Core Antibody): Indicates past or current infection
- Liver Function and Fibrosis Assessment Tests:
- ALT (Alanine Aminotransferase) and AST (Aspartate Aminotransferase): Liver enzyme markers; elevated levels indicate hepatocellular inflammation
- Alkaline Phosphatase and Bilirubin: Assess cholestasis and hepatic synthetic function
- Albumin and Prothrombin Time (PT/INR): Assess synthetic liver function and prognosis
- Platelet Count: Reflects portal hypertension severity; low counts suggest advanced cirrhosis
- FibroTest/FibroScan: Non-invasive fibrosis staging; transient elastography assesses liver stiffness
- APRI Score: Combines AST and platelet count to estimate fibrosis
- Viral Genotyping and Mutation Analysis:
- HBV Genotyping: Determines viral strain (A-H); guides treatment selection and prognosis assessment
- Resistance Mutation Testing: Screens for YMDD, BCP, and precore mutations when virological breakthrough occurs
- Screening for Co-infections:
- Anti-HDV (Hepatitis Delta Antibody/RNA): HDV only infects HBV-positive patients; associated with severe disease
- Anti-HCV (Hepatitis C Antibody) and HCV RNA: Screen for HCV co-infection
- HIV Testing: Important in at-risk populations; HIV co-infection affects HBV progression and therapy
- Cancer Surveillance:
- Alpha-fetoprotein (AFP): Tumor marker for HCC detection in patients with cirrhosis
- Abdominal Ultrasound: Annual screening in cirrhotic patients for HCC surveillance
- CT or MRI: Advanced imaging if HCC is suspected
- Monitoring Schedule:
- Untreated Chronic HBV: HBV DNA, liver function tests, and serological markers every 6-12 months
- During Treatment: HBV DNA at baseline, 4-12 weeks, 6 months, then every 6-12 months during therapy
- Post-Treatment: HBV DNA and HBsAg annually for at least 3 years to detect relapse
- Cirrhotic Patients: HBV DNA and HCC screening (ultrasound + AFP) every 6 months
Section 6: Fasting Required?
- Fasting Required: No
- Details: HBV DNA quantitative testing can be performed on blood samples collected at any time of day with or without food intake. Fasting is not required for this assay.
- Patient Preparation Requirements:
- No specific preparation is needed prior to blood collection
- Patient should arrive with proper identification and insurance information
- Standard venipuncture will be performed using a sterile needle and appropriate collection tube (typically EDTA or serum separator tube)
- Medications:
- No medications need to be discontinued before HBV DNA testing
- Continue taking all prescribed antiviral therapy and other medications as scheduled
- Timing of sample collection is not affected by meals or medication intake
- Special Instructions:
- Ensure consistent sample collection timing if serial testing is being performed for accurate comparison (same time of day recommended)
- Blood samples should be processed promptly and stored appropriately per laboratory protocol to ensure accurate results
- Inform healthcare provider of current antiviral therapy and any recent medication changes

How our test process works!